Key result
Beta-adrenergic blockers represent a major advance in pharmacotherapy, providing primary protection against cardiovascular morbidity and mortality in hypertensive patients.
This historical review highlights the development, mechanisms, and clinical applications of beta-blockers in cardiovascular medicine.
Answers are grounded in this paper and cite their sources.
Supports beta-blocker benefits in hypertension from historical data; leaves open optimal contemporary positioning pending modern trials.
The introduction of β‐adrenergic‐blocking drugs into clinical medicine in the early 1960s represented a major advance in pharmacotherapy. The use of these drugs highlighted the importance of the sympathetic nervous system in contributing to the pathophysiology of a wide variety of cardiovascular and noncardiovascular disorders. This article summarizes the history of β‐blocking agents and reviews the applications of this therapeutic class. These drugs may be useful as primary protection against cardiovascular morbidity and mortality in hypertensive patients and have proved to be beneficial in other cardiovascular conditions. Not all β‐blockers have the same mechanism of action and, among them, there are pharmacologic differences that may be of clinical importance.
No takes yet. Share an insight, caveat, or question.
William H. Frishman (2007) conducted a review in Cardiovascular disorders and hypertension. β-adrenergic blockers was evaluated. Beta-adrenergic blockers represent a major advance in pharmacotherapy, providing primary protection against cardiovascular morbidity and mortality in hypertensive patients.
Synapse has enriched 10 related papers. Consider them for comparative context: